Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022

Simple item page
dc.contributor.authorTobolowsky, Farrell A
dc.contributor.authorNsubuga, Fred
dc.contributor.authorGilani, Zunera
dc.contributor.authorKisakye, Annet
dc.contributor.authorNdagije, Helen
dc.contributor.authorKyabayinze, Daniel
dc.contributor.authorGidudu, Jane F
dc.date.accessioned2024-04-04T10:00:36Z
dc.date.available2024-04-04T10:00:36Z
dc.date.issued2024-04
dc.description.abstractAbstract Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of passive and active surveillance.en_US
dc.identifier.citationTobolowsky, Farrell A., Fred Nsubuga, Zunera Gilani, et al. 'Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022', Emerging Infectious Diseases, vol. 30/no. 4, (2024), pp. 775-778.en_US
dc.identifier.issnISSN 1080-6040
dc.identifier.issnEISSN 1080-6059
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/9470
dc.language.isoenen_US
dc.publisherCenters for Disease Control and Preventionen_US
dc.subjectvaccine-related paralysis; novel oral poliovirus vaccine type 2; Safety Evaluation; Immunization; Ugandaen_US
dc.titleNovel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
23-1361.pdf
Size:
400.32 KB
Format:
Adobe Portable Document Format
Description:
Journal Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences